Furthermore, a preclinical study demonstrated that CTLA-4 and PD-1 ICI increased CD8 + T-cell intratumoral infiltration compared to anti-CTLA-4 monotherapy, increasing the rate of tumor-free survival in melanoma mouse models by ~ 65% [19]. This evidence concerns the gene CTLA4 and melanoma.